Hodges, Michael R.

Voriconazole versus Amphotericin B for Primary Therapy of Invasive Aspergillosis

Herbrecht, R., Denning, D. W., Patterson, T. F., Bennett, J. E., Greene, R. E., Oestmann, J.-W., Kern, W. V., Marr, K. A., Ribaud, P., Lortholary, O., et al. (2002) · New England Journal of Medicine

Antifungal resistance and susceptibilityFungal and yeast genetics research

Cited by 3,304

Voriconazole in the treatment of aspergillosis, scedosporiosis and other invasive fungal infections in children

WALSH, T. J., LUTSAR, I., DRISCOLL, T., DUPONT, B., RODEN, M., GHAHRAMANI, P., HODGES, M., GROLL, A. H., & PERFECT, J. R. (2002) · The Pediatric Infectious Disease Journal

Antifungal resistance and susceptibilityFungal Infections and Studies

Cited by 431

A Randomized, Double‐Blind, Double‐Dummy, Multicenter Trial of Voriconazole and Fluconazole in the Treatment of Esophageal Candidiasis in Immunocompromised Patients

Ally, R., Schürmann, D., Kreisel, W., Carosi, G., Aguirrebengoa, K., Dupont, B., Hodges, M., Troke, P., Romero, A. J., & the Esophageal Candidiasis Study Group (2001) · Clinical Infectious Diseases

Antifungal resistance and susceptibilityFungal Infections and Studies

Cited by 331

Clinical Efficacy and Safety of a Novel Antifungal, Fosmanogepix, in Patients with Candidemia Caused by Candida auris : Results from a Phase 2 Trial

Vazquez, J. A., Pappas, P. G., Boffard, K., Paruk, F., Bien, P. A., Tawadrous, M., Ople, E., Wedel, P., Oborska, I., & Hodges, M. R. (2023) · Antimicrobial Agents and Chemotherapy

Antifungal resistance and susceptibilityFungal Infections and Studies

Cited by 92

Clinical safety and efficacy of novel antifungal, fosmanogepix, for the treatment of candidaemia: results from a Phase 2 trial

Pappas, P. G., Vazquez, J. A., Oren, I., Rahav, G., Aoun, M., Bulpa, P., Ben-Ami, R., Ferrer, R., Mccarty, T., Thompson, G. R., et al. (2023) · Journal of Antimicrobial Chemotherapy

Antifungal resistance and susceptibilityFungal Infections and Studies

Cited by 65

Safety and Pharmacokinetics of Intravenous and Oral Fosmanogepix, a First-in-Class Antifungal Agent, in Healthy Volunteers

Hodges, M. R., Ople, E., Wedel, P., Shaw, K. J., Jakate, A., Kramer, W. G., Marle, S. V., van Hoogdalem, E.-J., & Tawadrous, M. (2023) · Antimicrobial Agents and Chemotherapy

Antifungal resistance and susceptibilityFungal Infections and Studies

Cited by 52

Quantitative Systems Pharmacology Model of hUGT1A1‐modRNA Encoding for the UGT1A1 Enzyme to Treat Crigler‐Najjar Syndrome Type 1

Apgar, J. F., Tang, J., Singh, P., Balasubramanian, N., Burke, J., Hodges, M. R., Lasaro, M. A., Lin, L., Miliard, B. L., Moore, K., et al. (2018) · CPT: Pharmacometrics & Systems Pharmacology

Neonatal Health and BiochemistryPharmacogenetics and Drug Metabolism

Cited by 47

Absorption, Distribution, and Excretion of 14C-APX001 after Single-Dose Administration to Rats and Monkeys

Mansbach, R., Shaw, K. J., Hodges, M. R., Coleman, S., & Fitzsimmons, M. E. (2017) · Open Forum Infectious Diseases

Pharmacogenetics and Drug MetabolismAntifungal resistance and susceptibility

Cited by 21

147. Clinical Safety and Efficacy of Novel Antifungal, Fosmanogepix, in the Treatment of Candidemia: Results from a Phase 2 Proof of Concept Trial

Pappas, P., Kullberg, B. J., Vazquez, J. A., Oren, I., Rahav, G., Aoun, M., Bulpa, P., Ben-Ami, R., Ferrer, R., McCarty, T. P., et al. (2020) · Open Forum Infectious Diseases

Antifungal resistance and susceptibilityFungal Infections and Studies

Cited by 17